Lipoprotein(a): The Cholesterol Test Most People Have Never Had

Most people who have had their cholesterol checked assume the results tell the full story. They rarely do. There is a major cardiovascular risk factor that standard lipid panels completely ignore, and it is called lipoprotein(a), often written as Lp(a).

Up to one in five people carry elevated Lp(a) levels, yet the vast majority have never been tested. Unlike LDL cholesterol, which responds well to diet and statins, Lp(a) is almost entirely determined by your genes. That makes it both uniquely frustrating and uniquely important to know about.

What Is Lipoprotein(a) and Why Does It Matter?

Lp(a) is a variant of LDL cholesterol with an extra protein, called apolipoprotein(a), attached to its surface. This additional protein gives the particle a dual threat profile. It contributes to plaque build-up inside artery walls just like regular LDL, but it also interferes with the body's clot-dissolving mechanisms, making blood clots more likely to form and persist.

The result is a compounding of cardiovascular risk. Elevated Lp(a) has been consistently linked to:

• Coronary artery disease and heart attack
• Aortic valve stenosis (narrowing and calcification of the aortic valve)
• Ischaemic stroke
• Peripheral arterial disease

Because Lp(a) promotes both atherosclerosis and thrombosis through separate biological pathways, it can accelerate cardiovascular disease even in people whose other lipid numbers look reassuringly normal.

Why Standard Cholesterol Tests Miss It

A typical lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Lp(a) is not included in this panel unless a clinician specifically requests it.

What makes this particularly problematic is that the cholesterol carried by Lp(a) particles is counted within the LDL cholesterol number on your standard test. So a person with an LDL of 3.5 mmol/L might assume their risk is moderate, without realising that a substantial portion of that LDL is actually the more dangerous Lp(a) variety. The overall number looks the same, but the risk profile is meaningfully different.

A Once-in-a-Lifetime Test

Unlike most blood markers, Lp(a) levels are remarkably stable throughout adult life. They are set primarily by genetics, specifically by the LPA gene, and are not significantly altered by diet, exercise, weight loss, or most existing medications.

This is why many cardiovascular guidelines, including those from the European Atherosclerosis Society, recommend measuring Lp(a) at least once in every adult's lifetime. A single measurement gives you a number that is unlikely to change and tells you whether you are carrying a hidden risk factor that no amount of lifestyle modification will address on its own.

The test itself is a simple blood draw. It can be ordered alongside routine blood work, and results are typically reported in nmol/L. Values above 125 nmol/L (approximately 50 mg/dL) are generally considered elevated, though risk exists on a continuum.

Who Should Get Tested?

The short answer is: ideally, everyone, at least once. But testing is especially important if you have:

• A personal history of premature cardiovascular disease (heart attack or stroke before age 55 in men, 65 in women)
• A family history of early heart disease or sudden cardiac death
• Familial hypercholesterolaemia or very high LDL that does not fully respond to treatment
• Recurrent cardiovascular events despite apparently well-managed risk factors
• Aortic valve stenosis, particularly if diagnosed at a younger age

If you fall into any of these categories and have never had Lp(a) measured, it is worth raising the topic with your doctor. Many clinicians simply do not think to order it, not because they consider it unimportant, but because it has not yet become part of routine practice in most healthcare systems.

What a High Result Changes in Practice

Discovering you have elevated Lp(a) does not mean there is nothing to be done. It means the strategy shifts.

Because Lp(a) itself cannot currently be lowered effectively with approved therapies, management focuses on aggressively reducing every other modifiable risk factor. Think of it as reducing the total burden on your cardiovascular system so that the fixed contribution from Lp(a) matters less in absolute terms.

Practical steps typically include:

• Tighter LDL targets. Your clinician may aim for a lower LDL cholesterol goal than would otherwise be recommended, using statins, ezetimibe, or PCSK9 inhibitors as appropriate.
• Blood pressure optimisation. Even borderline hypertension becomes worth treating more assertively.
• Glycaemic control. If you have prediabetes or diabetes, tighter glucose management carries extra importance.
• Lifestyle intensification. Smoking cessation, regular exercise, and a cardioprotective dietary pattern all become non-negotiable rather than advisory.
• Aspirin or antiplatelet therapy. In selected cases, clinicians may consider low-dose aspirin, though this is an individualised decision based on bleeding risk.

Knowing your Lp(a) can also change how your clinician interprets imaging results and decides on the timing of interventions such as coronary angiography or valve surveillance.

The 2026 Horizon: Targeted Therapies on the Way

The treatment landscape for high Lp(a) is on the verge of transformation. Several targeted therapies are in late-stage clinical trials, with results expected to shape regulatory decisions in 2025 and 2026.

The most advanced candidates use antisense oligonucleotide or small interfering RNA technology to reduce the liver's production of apolipoprotein(a). Early-phase data have shown Lp(a) reductions of 80% or more, which would be unprecedented for a risk factor previously considered untreatable.

If these trials demonstrate a reduction in cardiovascular events, not just Lp(a) levels, we could see the first approved Lp(a)-lowering medications within the next one to two years. This would fundamentally change the clinical significance of knowing your number. A result that today prompts indirect risk management could soon lead to a direct, targeted prescription.

Getting tested now means you will be positioned to benefit from these therapies the moment they become available, rather than discovering your Lp(a) status only after a cardiovascular event forces the question.

How to Get Your Lp(a) Tested

In many EU countries, Lp(a) testing is available through your general practitioner or cardiologist, though you may need to request it specifically. Some direct-to-consumer laboratory services also offer Lp(a) measurement, but interpreting the result in clinical context is just as important as getting the number.

A telehealth consultation can be a practical first step, particularly if you want to discuss whether testing is appropriate for your situation, review results you have already received, or talk through what an elevated level means for your overall risk management plan. Platforms like AETHERA Health offer physician consultations that can help bridge the gap between a lab result and a personalised action plan, complementing the care you receive from your in-person medical team.

The Bottom Line on Lp(a)

Lp(a) is one of the strongest genetically determined risk factors for cardiovascular disease, yet it remains one of the least tested. A single blood draw can reveal whether you are carrying a hidden risk that your standard cholesterol panel has been quietly overlooking.

With targeted therapies potentially reaching the market in the near future, there has never been a better time to know your number. If you have not been tested, ask your doctor, or speak with a licensed clinician through a telehealth service to find out whether Lp(a) testing should be part of your cardiovascular risk assessment.

This article is for informational purposes only and does not constitute personalised medical advice. Always consult a licensed physician before making decisions about testing, diagnosis, or treatment.